Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jan;3(1):66-70.
doi: 10.4103/2278-330X.126531.

Management of relapsed-refractory diffuse large B cell lymphoma

Lalit S Raut  1 , Prantar P Chakrabarti  1
Affiliations
Review

Management of relapsed-refractory diffuse large B cell lymphoma

Lalit S Raut et al. South Asian J Cancer. 2014 Jan.

Abstract

Relapsed-Refractory Diffuse Large B Cell Lymphoma (RR DLBCL), which accounts for approximately one-third of patients with DLBCL, remains a major cause of morbidity and mortality. Managing RR DLBCL continues to be a challenge to the treating hemato-oncologist. Salvage high-dose chemotherapy followed by autologous stem cell transplantation is the standard of care for chemosensitive relapses in DLBCL. Various salvage regimens are available, but the quest for an optimal regimen continues. The addition of rituximab to the salvage regimen has improved the outcome of RR DLBCL. Several pertinent issues regarding the management of RR DLBCL are discussed in this short review.

Keywords: Activated B cell; autologous stem cell transplant; diffuse large B cell lymphoma; germinal center B; high dose chemotherapy; relapsed refractory.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

References

    1. Cancer Facts and Figures 2012. American Cancer Society. [Last accessed in 2013 Jan]. Available from: http://www.cancer.org .
    1. de Leval L, Hasserjian RP. Diffuse Large B-Cell Lymphomas and Burkitt Lymphoma. Hematol Oncol Clin North Am. 2009;23:791–827. - PubMed
    1. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: Evolving concepts and practical applications. Blood. 2011;117:5019–32. - PMC - PubMed
    1. Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, et al. Stromal gene signatures in large B cell lymphomas. N Engl J Med. 2008;359:2313–23. - PMC - PubMed
    1. Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med. 2010;362:1417–29. - PMC - PubMed